Humanigen’s stock tumbles 67% after sharing new clinical data for its COVID-19 treatment

Shares of Humanigen Inc. HGEN, -0.99% plunged 67.9% in premarket trading on Wednesday, the day after the company said a National Institutes of Health clinical trial testing lenzilumab and Gilead Sciences Inc.’s GILD, -0.51% Veklury in hospitalized COVID-19 patients did not produce the same benefit as it did in previous studies. Humanigen’s stock is down 19.6% this year, while the S&P 500 SPX, -0.92% has declined 19.9%.

 » Read More  » Read More

Tags: No tags

Comments are closed.